{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:57:51Z","timestamp":1785581871510,"version":"3.56.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Viruses"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Crimean-Congo hemorrhagic fever virus (CCHFV) is the causative agent of a severe hemorrhagic fever in humans, associated with case fatality rates up to 40%. Due to the lack of approved vaccines or specific antiviral treatments, CCHFV is classified as a biosafety level 4 (BSL4) pathogen in most countries and designated a priority pathogen by the World Health Organization. To facilitate the preclinical assessment of medical countermeasures, we have established a murine model using C57BL\/6J IFNAR\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    mice, which lack the IFN\u03b1\/\u03b2 receptor, infected with the phylogenetically distinct CCHFV strains Afghanistan09-2990 (Afg09) and Kosovo Hoti (Hoti). Infection with both CCHFV strains in IFNAR\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    mice resulted in significant weight loss, with Afg09 infection leading to more severe clinical disease. Quantitative analysis of viral RNA revealed widespread viral dissemination across multiple organs. Detection of infectious virus varied by organ and strain. These results independently validate previously reported disease phenotypes while providing new insight into strain-specific differences in CCHFV pathogenesis in IFNAR\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    mice. Thereby, these CCHFV models represent valuable tools for the evaluation of antiviral therapeutics and vaccine candidates, enabling the investigation of cross-lineage protection against genetically diverse CCHFV isolates.\n                  <\/jats:p>","DOI":"10.1038\/s44298-026-00216-2","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T21:44:49Z","timestamp":1785534289000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Side-by-side evaluation of two Crimean-Congo hemorrhagic fever virus isolates in IFNAR\u2212\/\u2212 mice"],"prefix":"10.1038","volume":"4","author":[{"given":"Cornelius","family":"Rohde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke-Dorothee","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Gellhorn Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Emmerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nata\u0161a","family":"Knap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Eickmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Kr\u00e4hling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Kupke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"BSL4 Animal Facility Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Benz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Huxol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"K\u00e4mper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kl\u00fcver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Neubecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"216_CR1","unstructured":"WHO. Introduction to Crimean-Congo Haemorrhagic fever. Available at: https:\/\/cdn.who.int\/media\/docs\/default-source\/crs-crr\/2025-04-02_epi-win-cchf-overview-_-a.-leganddf0bf77c-c7d7-445f-8d98-0363bf87ea93.pdf?sfvrsn=a94552ed_1 (WHO, 2025)."},{"key":"216_CR2","doi-asserted-by":"publisher","first-page":"8834","DOI":"10.1128\/JVI.00752-06","volume":"80","author":"VM Deyde","year":"2006","unstructured":"Deyde, V. M., Khristova, M. L., Rollin, P. E., Ksiazek, T. G. & Nichol, S. T. Crimean-Congo hemorrhagic fever virus genomics and global diversity. J. Virol. 80, 8834\u20138842 (2006).","journal-title":"J. Virol."},{"key":"216_CR3","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41579-023-00871-9","volume":"21","author":"DW Hawman","year":"2023","unstructured":"Hawman, D. W. & Feldmann, H. Crimean-Congo haemorrhagic fever virus. Nat. Revi. Microbiol. 21, 463\u2013477 (2023).","journal-title":"Nat. Revi. Microbiol."},{"key":"216_CR4","unstructured":"WHO. Pathogens Prioritization. A Scientific Framework for Epidemic and Pandemic Research Prepardness. Available at https:\/\/cdn.who.int\/media\/docs\/default-source\/consultation-rdb\/prioritization-pathogens-v6final.pdf?sfvrsn=c98effa7_7&download=true (WHO, 2024)."},{"key":"216_CR5","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1093\/infdis\/jit061","volume":"207","author":"M Zivcec","year":"2013","unstructured":"Zivcec, M. et al. Lethal Crimean-Congo hemorrhagic fever virus infection in interferon \u03b1\/\u03b2 receptor knockout mice is associated with high viral loads, proinflammatory responses, and coagulopathy. J. Infect. Dis. 207, 1909\u20131921 (2013).","journal-title":"J. Infect. Dis."},{"key":"216_CR6","doi-asserted-by":"publisher","first-page":"11089","DOI":"10.1128\/JVI.01383-10","volume":"84","author":"DA Bente","year":"2010","unstructured":"Bente, D. A. et al. Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. J. Virol. 84, 11089\u201311100 (2010).","journal-title":"J. Virol."},{"key":"216_CR7","doi-asserted-by":"publisher","first-page":"e0005908","DOI":"10.1371\/journal.pntd.0005908","volume":"11","author":"AR Garrison","year":"2017","unstructured":"Garrison, A. R. et al. A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models. PLoS Negl. Trop. Dis. 11, e0005908 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"216_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53362-7","volume":"15","author":"SS Leventhal","year":"2024","unstructured":"Leventhal, S. S. et al. Antibodies targeting the Crimean-Congo Hemorrhagic Fever Virus nucleoprotein protect via TRIM21. Nat. Commun. 15, 9236 (2024).","journal-title":"Nat. Commun."},{"key":"216_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2427782","volume":"13","author":"TE Sorvillo","year":"2024","unstructured":"Sorvillo, T. E. et al. Inflammation associated with monocyte\/macrophage activation and recruitment corresponds with lethal outcome in a mouse model of Crimean-Congo haemorrhagic fever. Emerg. Microbes Infect. 13, 2427782 (2024).","journal-title":"Emerg. Microbes Infect."},{"key":"216_CR10","doi-asserted-by":"publisher","unstructured":"Lindquist, M. E. et al. Exploring Crimean-Congo hemorrhagic fever virus-induced hepatic injury using antibody-mediated type i interferon blockade in Mice. J. Virol. 92; https:\/\/doi.org\/10.1128\/JVI.01083-18 (2018).","DOI":"10.1128\/JVI.01083-18"},{"key":"216_CR11","doi-asserted-by":"publisher","unstructured":"Hawman, D. W. et al. Crimean-Congo hemorrhagic fever mouse model recapitulating human convalescence. J. Virol. 93; https:\/\/doi.org\/10.1128\/jvi.00554-19 (2019).","DOI":"10.1128\/jvi.00554-19"},{"key":"216_CR12","doi-asserted-by":"publisher","first-page":"e2804","DOI":"10.1371\/journal.pntd.0002804","volume":"8","author":"L Oestereich","year":"2014","unstructured":"Oestereich, L. et al. Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Negl. Trop. Dis. 8, e2804 (2014).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"216_CR13","doi-asserted-by":"publisher","first-page":"e1010485","DOI":"10.1371\/journal.ppat.1010485","volume":"18","author":"JW Golden","year":"2022","unstructured":"Golden, J. W. et al. The host inflammatory response contributes to disease severity in Crimean-Congo hemorrhagic fever virus-infected mice. PLoS Pathog. 18, e1010485 (2022).","journal-title":"PLoS Pathog."},{"key":"216_CR14","doi-asserted-by":"publisher","first-page":"S794","DOI":"10.1093\/clinids\/11.Supplement_4.S794","volume":"11","author":"R Swanepoel","year":"1989","unstructured":"Swanepoel, R. et al. The clinical pathology of Crimean-Congo hemorrhagic fever. Rev. Infect. Dis. 11, S794\u2013S800 (1989).","journal-title":"Rev. Infect. Dis."},{"key":"216_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114502","volume":"43","author":"OS Shin","year":"2024","unstructured":"Shin, O. S. et al. Crimean-Congo hemorrhagic fever survivors elicit protective non-neutralizing antibodies that target 11 overlapping regions on glycoprotein GP38. Cell Rep. 43, 114502 (2024).","journal-title":"Cell Rep."},{"key":"216_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.antiviral.2018.06.013","volume":"157","author":"DW Hawman","year":"2018","unstructured":"Hawman, D. W. et al. Favipiravir (T-705) but not ribavirin is effective against two distinct strains of Crimean-Congo hemorrhagic fever virus in mice. Antivir. Res. 157, 18\u201326 (2018).","journal-title":"Antivir. Res."},{"key":"216_CR17","doi-asserted-by":"publisher","first-page":"e1008183","DOI":"10.1371\/journal.ppat.1008183","volume":"15","author":"SR Welch","year":"2019","unstructured":"Welch, S. R. et al. Fluorescent Crimean-Congo hemorrhagic fever virus illuminates tissue tropism patterns and identifies early mononuclear phagocytic cell targets in Ifnar-\/- mice. PLoS Pathog. 15, e1008183 (2019).","journal-title":"PLoS Pathog."},{"key":"216_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijid.2016.02.1008","volume":"45","author":"NY Pshenichnaya","year":"2016","unstructured":"Pshenichnaya, N. Y., Sydenko, I. S., Klinovaya, E. P., Romanova, E. B. & Zhuravlev, A. S. Possible sexual transmission of Crimean-Congo hemorrhagic fever. Int. J. Infect. Dis. 45, 109\u2013111 (2016).","journal-title":"Int. J. Infect. Dis."},{"key":"216_CR19","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1515\/BC.2007.061","volume":"388","author":"O Boehm","year":"2007","unstructured":"Boehm, O. et al. Clinical chemistry reference database for Wistar rats and C57\/BL6 mice. Biol. Chem. 388, 547\u2013554 (2007).","journal-title":"Biol. Chem."},{"key":"216_CR20","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1080\/22221751.2019.1659552","volume":"8","author":"C Rohde","year":"2019","unstructured":"Rohde, C., Becker, S. & Kr\u00e4hling, V. Marburg virus regulates the IRE1\/XBP1-dependent unfolded protein response to ensure efficient viral replication. Emerg. Microbes Infect. 8, 1300\u20131313 (2019).","journal-title":"Emerg. Microbes Infect."},{"key":"216_CR21","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ymthe.2022.10.011","volume":"31","author":"V Kr\u00e4hling","year":"2023","unstructured":"Kr\u00e4hling, V. et al. Self-amplifying RNA vaccine protects mice against lethal Ebola virus infection. Mol. Ther. : J. Am. Soc. Gene Ther. 31, 374\u2013386 (2023).","journal-title":"Mol. Ther. : J. Am. Soc. Gene Ther."},{"key":"216_CR22","doi-asserted-by":"publisher","unstructured":"Tscherne, A. et al. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination. In Proc. National Academy of Sciences of the United States of America 118; https:\/\/doi.org\/10.1073\/pnas.2026207118 (2021).","DOI":"10.1073\/pnas.2026207118"},{"key":"216_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2021.112958","volume":"490","author":"V Kr\u00e4hling","year":"2021","unstructured":"Kr\u00e4hling, V. et al. Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies. J. Immunol. Methods 490, 112958 (2021).","journal-title":"J. Immunol. Methods"},{"key":"216_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00430-015-0438-6","volume":"205","author":"V Kr\u00e4hling","year":"2016","unstructured":"Kr\u00e4hling, V. et al. Development of an antibody capture ELISA using inactivated Ebola Zaire Makona virus. Med. Microbiol. Immunol. 205, 173\u2013183 (2016).","journal-title":"Med. Microbiol. Immunol."}],"container-title":["npj Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44298-026-00216-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44298-026-00216-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44298-026-00216-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:02:17Z","timestamp":1785578537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44298-026-00216-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["216"],"URL":"https:\/\/doi.org\/10.1038\/s44298-026-00216-2","relation":{},"ISSN":["2948-1767"],"issn-type":[{"value":"2948-1767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"4 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"35"}}